-
EMD638683: From SGK1 Target to Assay Logic
2026-09-21
EMD638683 is an SGK1 inhibitor for dissecting kinase-dependent control of endothelial mechanics, NDRG1 signaling, and tumor-cell responses. This evidence-focused guide explains how to choose readouts, interpret selectivity, and connect vascular and oncology applications without overstating preclinical findings.
-
Protease Inhibitor Cocktail for Plant Extracts
2026-09-21
Protect labile plant proteins, phosphoproteins, and interaction partners during extraction with an EDTA-free, broad-spectrum inhibitor system. This workflow shows how to apply it to Arabidopsis aluminum-stress studies, Western blots, co-immunoprecipitation, pull-downs, and kinase assays while avoiding common assay-interference problems.
-
SC 79: A Causal Map of Akt Signaling
2026-09-20
SC 79 is an Akt activator for dissecting cytosolic kinase control, neuronal survival, and inflammatory senescence. This guide connects its mechanism with SIRT7–AKT/mTOR findings to improve assay design and interpretation.
-
nor-NOHA Acetate Workflows for Arginase Research
2026-09-19
Use nor-NOHA acetate to connect reversible arginase inhibition with cancer-cell phenotyping, endothelial assays, and immunometabolic co-cultures. This workflow-focused guide separates established HepG2 and vascular findings from exploratory applications inspired by CD36-driven immune escape in AML.
-
Canine Osteosarcoma Cells: NSAID Cytotoxicity
2026-09-19
Royals and colleagues compared deracoxib and piroxicam in three canine osteosarcoma cell lines and a fibroblast line, showing concentration-dependent tumor-cell toxicity without evidence of DNA-fragmentation apoptosis. The study provides a useful framework for interpreting selective in vitro cytotoxicity, while also demonstrating why high experimental concentrations should not be equated with clinical antitumor activity.
-
Actinomycin D: Stress-Test the HuR–BIRC3 Axis
2026-09-18
Actinomycin D can move translational HCC research beyond correlation by providing a controlled transcriptional shutoff experiment for testing BIRC3 mRNA stability within the circNUP54–HuR–BIRC3–NF-κB axis. This article explains the mechanism, experimental design, interpretation limits, and strategic value of ActD as a complementary probe rather than a standalone cytotoxicity readout.
-
5-(N,N-dimethyl)-Amiloride: NHE1 Workflow
2026-09-18
Use 5-(N,N-dimethyl)-Amiloride hydrochloride as a mechanistic probe for intracellular pH regulation, endothelial barrier dysfunction, and cardiac ion-transport studies. This workflow combines isoform-aware dosing with moesin and permeability readouts, helping distinguish Na+/H+ exchanger effects from broader cytotoxic or metabolic artifacts.
-
Self-Amplifying Nppa RNA Protects the Injured Heart
2026-09-17
The reference study develops a single-dose intramuscular lipid nanoparticle containing self-amplifying Nppa RNA to provide sustained pro-ANP production after myocardial infarction. Across mouse and swine injury models, this strategy improved cardiac function and limited infarction, fibrosis, and pathological remodeling while avoiding the need for direct cardiac injection.
-
Mitochondrial Permeability Transition Pore Assay Kit Guide
2026-09-17
Learn how to use the Mitochondrial Permeability Transition Pore Assay Kit for live-cell mitochondrial permeability studies, from Calcein AM loading to cobalt-quenching controls. The workflow is especially useful for connecting pore opening with oxidative stress, membrane potential, apoptosis, and disease-relevant primary-cell phenotypes.
-
GSTA1 and α-Amanitin Hepatotoxicity: A Redox Paradox
2026-09-16
The reference study identifies GSTA1 as an unexpected driver of α-amanitin-induced liver injury rather than a purely protective antioxidant enzyme. By combining mouse toxicology, multi-omics, target-interaction assays, and genetic experiments, it links GSTA1 upregulation to glutathione depletion, reactive oxygen species accumulation, and hepatocyte damage.
-
Vernakalant PK/PD in Atrial Fibrillation
2026-09-15
This 2011 population pharmacokinetic–pharmacodynamic study integrated data from five clinical trials to characterize vernakalant exposure, QTcF prolongation, systolic blood pressure, and hypotension risk in atrial fibrillation or flutter. Its main contribution was to connect concentration–response behavior with conversion status, clarifying why an atrial-selective antiarrhythmic can support rapid rhythm conversion while producing comparatively limited ventricular and blood-pressure effects.
-
Açaí Extracts: Hepatocyte Cytotoxicity and Induction
2026-09-15
Raichura and colleagues developed an integrated human hepatocyte and transporter-screening strategy to distinguish açaí extract cytotoxicity from induction of major drug-metabolizing pathways. Selected solvent extracts reduced hepatocyte viability in a time- and dose-dependent manner, but the study found no significant induction of the tested CYP enzymes or transporters, emphasizing the need for formulation-specific botanical-drug interaction assessment.
-
Recombinant Human Oncostatin M Assay Workflows
2026-09-14
Build reproducible fibroblast, TF-1, and cytokine-release experiments with a defined rh-Oncostatin M perturbation. This guide connects OSM dose finding with senescence, mitochondrial-quality, and proliferation readouts while separating established product performance from exploratory applications.
-
IGF2BP1–TUBB4B m6A Axis in Liver Fibrosis
2026-09-14
The reference study identifies an IGF2BP1–TUBB4B–FAK pathway that links m6A-dependent RNA stabilization to hepatic stellate cell activation and liver fibrosis. Its combination of transcriptomic re-analysis, molecular perturbation, and pharmacological testing provides a useful framework for separating RNA-regulatory mechanisms from downstream proliferation and migration phenotypes.
-
TaqI Restriction Endonuclease Protocol Guide
2026-09-13
TaqI Restriction Endonuclease (SKU K3053) provides sequence-specific cleavage at 5′-TCGA-3′ for rapid processing of plasmids, PCR products, and genomic DNA, with product documentation specifying a 5–15-minute digestion window. It is intended for research cloning and DNA analysis workflows, not diagnostic, clinical, or medical use, and reaction conditions should be validated for each substrate.